Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 20/20 | 0.58 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | CASP7 | P55210 | 1/20 | 0.51 |
| ▸ | CASP9 | P55211 | 1/20 | 0.51 |
| ▸ | CASP6 | P55212 | 1/20 | 0.51 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.51 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11919339 | 0.90 | TDP2 (0.58) | TDP2CASP3CASP7CASP9CASP6 | |
| SCHEMBL18010818 | 0.80 | TDP2 (0.63) | TDP2CASP3CASP7CASP9CASP6 | |
| SCHEMBL578518 | 0.79 | AHR (0.56) | — | |
| SCHEMBL7121335 | 0.79 | AHR (0.56) | — | |
| SCHEMBL4509576 | 0.79 | AHR (0.56) | — | |
| SCHEMBL9920103 | 0.77 | TDP2 (0.64) | TDP2CASP3CASP7CASP9CASP6 | |
| SCHEMBL7901539 | 0.76 | CLK4 (0.49) | — | |
| SCHEMBL4894905 | 0.76 | ALDH1A1 (0.46) | — | |
| SCHEMBL25122776 | 0.75 | TDP2 (0.53) | TDP2CASP3CASP7CASP9CASP6 | |
| SCHEMBL11789436 | 0.75 | TDP2 (0.56) | TDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | TDP2 3011/4885CASP3 4064/4885CASP7 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.